About us

The Institute of Biomedicine of Seville (IBiS) is a multidisciplinary center whose objective is to carry out fundamental research on the causes and mechanisms of the most prevalent pathologies in the population and the development of new methods of diagnosis and treatment for them.

The IBiS is made up of 42 consolidated groups and 42 assigned groups led by researchers from the University of Seville, the Higher Council for Scientific Research (CSIC) and the Virgen del Rocío, Virgen Macarena and Virgen de Valme University Hospitals organized around five thematic areas: Infectious and Immune System Diseases, Neurosciences, Onco-hematology and Genetics, Cardiovascular Pathology, Respiratory / Other Systemic Pathologies and Liver, Digestive and Inflammatory Diseases.

The IBiS depends institutionally on the Department of Health and Consumer Affairs of the Junta de Andalucía; the Andalusian Health Service (SAS); the Department of University, Research and Innovation of the Junta de Andalucía; the University of Seville and the Higher Council for Scientific Research (CSIC), and is managed by the Foundation for the Management of Health Research of Seville (FISEVI) according to BOE Agreement 306 of December 22, 2022.

The Institute bases its fundamental research at the molecular or cellular level with the objective of immediate transfer of knowledge to clinical reality and the development of new therapies. This translational research, one of the genuine characteristics of IBiS, is only possible in structures that combine molecular medicine with quality clinical practice in one place.

The IBiS was the first research institute of the Andalusian Public Health System (SSPA) accredited by the Carlos III Health Institute. Its building of about 8,200 m2 houses 67 laboratories and dedicates more than 50% of its space to various central research support services, which employ around thirty technicians. Currently, the Institute has more than almost 1,000 researchers, who are part of the 42 Research Groups with a laboratory in the center or the 41 Assigned Groups. It has an administration and management structure that supports researchers, and also includes 3 Research Platforms: Biobank, Clinical Trials and Technological Innovation.